Schizophrenia is a chronic brain disorder affecting approximately 0.29% to 0.33% of the worldwide population, making it one of the most severe mental health conditions globally. While relatively uncommon compared to conditions like depression or anxiety, schizophrenia significantly impacts individuals, families, and healthcare systems due to its chronic nature and complex symptom profile.
Understanding the statistics and facts surrounding schizophrenia helps dispel myths, reduce stigma, and promote evidence-based knowledge about this often-misunderstood condition. From prevalence rates to mortality statistics, substance use comorbidity to treatment outcomes, the numbers tell an important story about both challenges and opportunities in schizophrenia care.
Table of Contents
- Global and U.S. Prevalence Statistics
- Demographics: Age, Gender, and Onset
- Life Expectancy and Mortality
- Suicide Risk and Prevention
- Substance Use and Comorbidity
- Symptoms and Clinical Features
- Economic Impact and Healthcare Burden
- Treatment Access and Outcomes
- Frequently Asked Questions
- How Therapy Can Help
Global and U.S. Prevalence Statistics
Schizophrenia affects millions of people worldwide, though exact prevalence varies by region and measurement methodology. Current data reveals:
Global Statistics
- Approximately 23 million people worldwide have schizophrenia, or 1 in 345 people (0.29%)
- Among adults specifically, the rate increases to 1 in 233 people (0.43%)
- Between 1990 and 2021, global prevalence increased from 13.62 million to 23.18 million cases
- Approximately 24 million people are affected globally, reflecting a prevalence rate of about 0.32%
United States Statistics
- The prevalence of schizophrenia and related psychotic disorders ranges from 0.25% to 0.75%
- In 2023, approximately 3.7 million American adults (1.8% of the population) reported experiencing schizophrenia spectrum disorders at some point in their lives
- About 1.2% of Americans (2.5 million individuals) in 2023 met the diagnostic criteria for schizophrenia
- The estimated prevalence in the U.S. ranges from 0.25% to 0.64%, equating to about 1.5 million adults affected each year
Demographics: Age, Gender, and Onset
Understanding who is most affected by schizophrenia helps target prevention and early intervention efforts:
Age of Onset
- Schizophrenia is typically diagnosed in late teens to early thirties, emerging earlier in males (late adolescence to early twenties) than females (early twenties to early thirties)
- Onset is most often during late adolescence and the twenties
- In 2023, schizophrenia was most prevalent among adults aged 26 to 44
Gender Differences
- Men are more likely to have a schizophrenia diagnosis than women, with 1.5% of men affected compared to 0.9% of women in 2023
- Males and females have approximately the same lifetime risk, but males are typically diagnosed 3 to 5 years earlier
- Males tend to experience more severe negative symptoms, while females may have better social functioning outcomes
Racial and Ethnic Disparities
- Black Americans have approximately twice the risk of being diagnosed with schizophrenia compared with white Americans
- Schizophrenia diagnosis is lowest in Asian and Hawaiian/Pacific Islander populations, while Hispanic and American Indian/Native Alaskan people have slightly higher prevalence than white populations
- A 2025 study found that increased risk in some populations corresponds more to structural inequities than genetic risk
Life Expectancy and Mortality
One of the most concerning aspects of schizophrenia is its impact on life expectancy:
Mortality Statistics
- The estimated average potential life lost for individuals with schizophrenia in the U.S. is 28.5 years
- Schizophrenia is associated with a weighted average of 14.5 years of potential life loss, higher for men (15.9 years) than women (13.6 years)
- People with schizophrenia die 15-20 years prematurely
- Individuals with schizophrenia face significantly higher mortality rates with a typical reduction in life expectancy of 15-20 years
Causes of Premature Death
- Premature mortality is mainly due to preventable natural causes, such as cardiovascular disease, infections, respiratory tract diseases, and cancer, alongside suicide, homicide, and accidents
- Co-occurring medical conditions, such as heart disease, liver disease, and diabetes, contribute to higher premature mortality rates
- In a 20-year follow-up study, the most common cause of death was suicide (27%)
Contributing Factors
- Smoking, alcohol/substance abuse, and sedentary lifestyle, alongside disease-related factors such as metabolic abnormalities and accelerating aging, contribute to physical morbidity
- The symptomatology of psychosis and stigma may limit patients' access to quality medical care
Suicide Risk and Prevention
Suicide represents a critical concern in schizophrenia care:
Suicide Statistics
- A lifetime suicide rate in individuals with schizophrenia is approximately 10%, and suicide is the largest contributor to decreased life expectancy
- Individuals with schizophrenia have a 4.9% lifetime risk of suicide, significantly higher than the general population
- People with schizophrenia have a 4.5-fold increased risk of dying from suicide
- Schizophrenic men had a suicide rate of 88.96 per 100,000 people, compared to 56.33 per 100,000 for women
Risk Factors and Timing
- Throughout the first decade of their disorder, patients are at substantially elevated suicide risk, with 44% of suicides occurring during the first decade, 22% during the second decade, and another 22% during the third decade
- The youngest age group (18-34) had the highest suicide risk, while those aged 65 and older had the lowest
- Suicide risk is significantly elevated during the first psychotic break
- Depression, substance use, and recent loss or stressful life events increase suicide risk
Prevention Considerations
- Expanding access to clozapine, treating co-occurring substance use disorders, making early psychosis detection programs widely available, and using cognitive behavioral therapy can help reduce suicide risk
- Regular screening and monitoring, especially during high-risk periods
- Addressing command hallucinations and maintaining medication adherence
Substance Use and Comorbidity
Substance use disorders (SUDs) frequently co-occur with schizophrenia:
Prevalence of Substance Use
- Nearly half of people with schizophrenia present with a lifetime history of substance use disorders
- SUD prevalence ranges from 26% (Finland) to 31% (Sweden) in national cohort studies
- One study found 47% of people with schizophrenia struggled with drug or alcohol abuse compared to 16% without the disorder
Common Substances
- Nicotine: National surveys have found smoking rates in people with schizophrenia as high as 90%
- Alcohol: Alcohol use disorders affect 21-45% of individuals with schizophrenia
- Cannabis: High rates of use, with heavy cannabis use associated with increased psychosis risk
- Multiple substances: Multiple drug use affects 48-67% of those with comorbid SUDs
Impact of Comorbidity
- Any SUD comorbidity in schizophrenia is associated with 50% to 100% increase in hospitalization and mortality risks
- Elevated mortality risk is observed especially for suicides and other external causes
- People with schizophrenia and substance abuse have higher rates of hospitalization, homelessness, aggression, violence, incarceration, and suicidality
Treatment Considerations
- The healthcare system often treats addiction and mental illness separately, leading to delays in proper diagnosis and treatment
- Integrated treatment addressing both conditions simultaneously shows better outcomes
- Clozapine has been shown to reduce psychotic symptoms in both schizophrenia and substance abuse
Symptoms and Clinical Features
Schizophrenia presents with diverse symptoms affecting multiple domains:
Positive Symptoms
- Hallucinations: Auditory hallucinations, or "hearing voices," are the most common in schizophrenia
- Delusions: Persecutory (paranoid) delusions are the most common type
- Disorganized thinking: Speech may be jumbled or unrelated to conversation topics
- Abnormal motor behavior: Can range from catatonia to unpredictable agitation
Negative Symptoms
- Reduced emotional expression (flat affect)
- Decreased motivation (avolition)
- Social withdrawal
- Reduced speech output
- Difficulty experiencing pleasure
Cognitive Symptoms
- Cognitive symptoms affect approximately 75% of individuals with the disorder
- Memory impairments
- Attention difficulties
- Problems with executive function
- Slowed information processing
Recovery and Outcomes
- At least one-third of people with schizophrenia experience complete remission of symptoms
- About 25% to 30% of individuals achieve a normal lifestyle without further problems after experiencing an episode of psychosis
- Recovery is certainly possible, though schizophrenia remains a severe and complex mental disorder
Economic Impact and Healthcare Burden
The economic burden of schizophrenia extends beyond direct healthcare costs:
Economic Costs
- The economic burden of schizophrenia in the United States in 2019 was $343.2 billion, more than doubled between 2013 and 2019
- Indirect costs accounted for 73.4% of the total burden ($251.9 billion)
- Direct healthcare costs amounted to $62.3 billion, representing 18.2% of the total
- Across the U.S. economy, serious mental illness causes $193.2 billion in lost earnings each year
Individual Financial Impact
- In 2021, schizophrenia led to an estimated lifetime fiscal loss of $1,540,042 per person to the U.S. government
- These losses were driven by healthcare costs (41.9%), criminal justice/homelessness (39.4%), and lost tax revenue (17.5%)
Healthcare Utilization
- Schizophrenia is one of the top 15 leading causes of disability worldwide
- High rates of emergency department visits and hospitalizations
- Significant burden on mental health services and state hospitals
Treatment Access and Outcomes
Despite available treatments, access remains a significant challenge:
Treatment Gaps
- Currently, the vast majority of people with schizophrenia around the world are not receiving mental health care, with only 29% of people with psychosis receiving specialist mental health care
- In 2023, 72.9% of adults who experienced schizophrenia in the past year received some method of mental health care
- 90% of women received care compared to 57% of men
Treatment Effectiveness
- Antipsychotic medications effectively manage positive symptoms in most cases
- Negative and cognitive symptoms show limited response to antipsychotic medications
- Psychosocial interventions improve functional outcomes
- Early intervention programs show promise for better long-term outcomes
Barriers to Treatment
- Stigma and discrimination
- Lack of awareness or insight into illness
- Limited access to specialized services
- Cost and insurance coverage issues
- Side effects of medications
Frequently Asked Questions
What percentage of the population has schizophrenia?
Schizophrenia affects approximately 1 in 345 people (0.29%) worldwide. In the United States, about 1.2% of Americans (2.5 million individuals) met the diagnostic criteria for schizophrenia in 2023.
At what age does schizophrenia typically develop?
Schizophrenia is typically diagnosed in late teens to early thirties, emerging earlier in males (late adolescence to early twenties) than females (early twenties to early thirties). However, subtle changes in cognition and social relationships may precede diagnosis by years.
How does schizophrenia affect life expectancy?
People with schizophrenia die 15-20 years prematurely, with an estimated average potential life lost of 28.5 years in the U.S. This is largely due to preventable medical conditions, suicide, and lifestyle factors.
What is the suicide risk for people with schizophrenia?
Individuals with schizophrenia have a 4.9% lifetime risk of suicide, with a 4.5-fold increased risk compared to the general population. The risk is highest in younger adults and during early illness stages.
How common is substance use in schizophrenia?
Nearly half of people with schizophrenia present with a lifetime history of substance use disorders. Smoking rates can be as high as 90%, significantly higher than the general population.
Can people with schizophrenia recover?
Yes, recovery is possible. At least one-third of people with schizophrenia experience complete remission of symptoms, and about 25% to 30% achieve a normal lifestyle without further problems after experiencing an episode of psychosis.
How Therapy Can Help
If you or a loved one is experiencing symptoms of schizophrenia, professional help is essential. Evidence-based treatments can significantly improve quality of life and functional outcomes. Treatment typically involves a combination of:
- Medication management to address psychotic symptoms
- Psychotherapy including cognitive behavioral therapy for psychosis
- Family therapy and psychoeducation
- Rehabilitation services for daily living skills
- Peer support and recovery-oriented programs
Early intervention is crucial – research shows that shorter duration of untreated psychosis leads to better outcomes. The therapists in our directory are experienced in treating schizophrenia spectrum disorders and can provide comprehensive, compassionate care tailored to individual needs.
Find a therapist experienced in schizophrenia treatment →
Remember, with proper treatment and support, many people with schizophrenia lead fulfilling, productive lives. Recovery is a journey, and professional help can make all the difference.
References:
- Chan, J. K. N., Correll, C. U., Wong, C. S. M., Chu, R. S. T., Fung, V. S. C., Wong, G. H. S., et al. (2023). Life expectancy and years of potential life lost in people with mental disorders: A systematic review and meta-analysis. eClinicalMedicine, 65, 102294. https://doi.org/10.1016/j.eclinm.2023.102294
- Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., et al. (2022). Mortality in people with schizophrenia: A systematic review and meta‐analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 21(2), 248–271. https://doi.org/10.1002/wps.20994
- Dickerson, F., Origoni, A., Khushalani, S., Bitan, S., Bell, M., Bennett, M., et al. (2024). Risk factors for natural cause mortality in schizophrenia. JAMA Network Open, 7(8), e2432401. https://doi.org/10.1001/jamanetworkopen.2024.32401
- Hajdúk, M., Harvey, P. D., Penn, D. L., & Pinkham, A. E. (2023). A systematic review and meta-analysis of the association between psychopathology and social functioning in schizophrenia. Schizophrenia Bulletin, 49(6), 1470–1485. https://doi.org/10.1093/schbul/sbad075
- Hansen, H. G., Speyer, H., Starzer, M. S. K., Albert, N., Hjorthøj, C., Eplov, L. F., & Nordentoft, M. (2023). The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. Schizophrenia Research, 250, 152-163. https://doi.org/10.1016/j.schres.2022.11.010
- Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 234-258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
- Institute for Health Metrics and Evaluation. (2025). Global Burden of Disease Study 2023 (GBD 2023). Seattle, United States: University of Washington. Available from https://vizhub.healthdata.org/gbd-results/
- Martin, R., Rui, L., et al. (2023). The lifetime burden of schizophrenia as estimated by a government-centric fiscal analytic framework. Psychiatric Services, 74(8), 789-798. https://doi.org/10.1176/appi.ps.202200241
- National Alliance on Mental Illness. (2025). Mental health by the numbers. Retrieved from https://www.nami.org/about-mental-illness/mental-health-by-the-numbers/
- National Institute of Mental Health. (2025). Schizophrenia statistics. Retrieved from https://www.nimh.nih.gov/health/statistics/schizophrenia
- Olfson, M., Stroup, T. S., Huang, C., Wall, M. M., Crystal, S., & Gerhard, T. (2021). Suicide risk in Medicare patients with schizophrenia across the life span. JAMA Psychiatry, 78(8), 876–885. https://doi.org/10.1001/jamapsychiatry.2021.0841
- Solmi, M., Seitidis, G., Mavridis, D., Correll, C. U., Dragioti, E., Guimond, S., et al. (2023). Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry, 28, 5319–5327. https://doi.org/10.1038/s41380-023-02138-4
- Starzer, M. S. K., Hansen, H. G., Hjorthøj, C., Speyer, H., Albert, N., & Nordentoft, M. (2023). Predictors of mortality following a schizophrenia spectrum diagnosis: Evidence from the 20-year follow-up of the OPUS randomized controlled trial. Schizophrenia Bulletin, 49(5), 1256–1268. https://doi.org/10.1093/schbul/sbad111
- Substance Abuse and Mental Health Services Administration & RTI International. (2023). Mental and substance use disorders prevalence study. Retrieved from https://www.samhsa.gov/data/
- World Health Organization. (2025, October 6). Schizophrenia fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/schizophrenia
